P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
G. Riely , C. Lovly , C. Messina , S. Bienert
Journal of Thoracic Oncology 14 ( 10)
2019
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
H.A. Yu , C. Sima , D. Feldman , L.L. Liu
Annals of Oncology 28 ( 2) 278 -284
48
2016
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J. Weiss , M. L. Sos , D. Seidel , M. Peifer
Science Translational Medicine 2 ( 62) 62 -93
944
2010
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
J. Chmielecki , J. Foo , G. R. Oxnard , K. Hutchinson
Science Translational Medicine 3 ( 90)
391
2011
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
C. M. Lovly , W. Pao
Science Translational Medicine 4 ( 120)
86
2012
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
D. B. Solit , P. B. Paty , D. Rohle , I. Vivanco
Proceedings of the National Academy of Sciences of the United States of America 106 ( 23) 9435 -9440
193
2009
Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives
Q. Wang , J. Xia , P. Jia , W. Pao
Briefings in Bioinformatics 14 ( 4) 506 -519
116
2013
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma.
M. L. Johnson , C. Sima , P. K. Paik , Y. Y. Janjigian
Journal of Clinical Oncology 28 7541 -7541
3
2010
“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
C. Grommes , G. R. Oxnard , M. G. Kris , V. A. Miller
Neuro-oncology 13 ( 12) 1364 -1369
260
2011
Oncogenes come of age.
H. VARMUS , W. PAO , K. POLITI , K. PODSYPANINA
Cold Spring Harbor Symposia on Quantitative Biology 70 1 -9
31
2005
Rapid detection of epidermal growth factor receptor mutations in lung cancer by the smart-amplification process. Commentary
William PAO , Marc LADANYI , Yuki KAWAI , Yasushi KOGO
Clinical cancer research 13 ( 17)
2007
SECTION J
PIERRE P MASSION , LECIA V SEQUIST , WILLIAM PAO
IF2013: 1.016 Total Cites: 6003 5 years IF: 1.077
REN Guo-ping , Y Theresa , PAN Qiu-lu , PAO William
Chinese Medical Journal 118 ( 9) 769 -771
2005
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Valerie W. Rusch , Mark G. Kris , Marc Ladanyi , Michelle S. Ginsberg
Archives of Pathology & Laboratory Medicine 133 ( 3) 470 -477
41
2009
Serum levels of surfactant protein D are increased in mice with lung tumors.
Lori D Dwyer-Nield , Sarah M Umphress , Sonia B Jakowlew , Alvin M Malkinson
Cancer Research 63 ( 18) 5889 -5894
24
2003
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Valerie Rusch , Gregory Riely , William Gerald , Adi Gazdar
Molecular Cancer Therapeutics 6
1,867
2007
Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma.
Qiu-lu Pan , William Pao , Jing Huai , Theresa Y Wang
Chinese Medical Journal 118 ( 9) 769 -771
3
2005
Abstract PR05: ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm+) and resistance (T790M) mutations in NSCLC
Cath Eberlein , Katie Al-Kadhimi , Sarah Ross , Henry Brown
Clinical Cancer Research 21
2015
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G Azzoli , Sherman Baker Jr , Sarah Temin , William Pao
Journal of Clinical Oncology 27 ( 36) 6251 -6266
828
2009
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
Leora Horn , William Pao
Journal of Clinical Oncology 27 ( 26) 4232 -4235
436
2009